Note: The percentages are from pooled data in adults with B-cell malignancies; the Prescribing Information sentence lists the most common adverse reactions in CLL/SLL without percentages.
What are the most common grade 3 or higher side effects of Imbruvica?
Applies to Adults with B-cell malignancies, including CLL/SLL (pooled label safety data)
Note: The 1,284-patient long-term analysis, the source of the Grade 3 or greater hypertension rates, included patients with B-cell malignancies (warnings and precautions page); the rollover and follow-up pool of CLL/SLL patients is N=808.
What side effects occurred with Imbruvica vs chlorambucil (RESONATE-2)?
Applies to Adults with previously untreated (first-line) CLL/SLL
Note: Table columns are Imbruvica all grades, Imbruvica Grade 3 or higher, chlorambucil all grades, and chlorambucil Grade 3 or higher (% of patients).
What side effects occurred with Imbruvica vs ofatumumab in relapsed CLL (RESONATE)?
Applies to Adults with previously treated (relapsed or refractory) CLL/SLL
Note: Table columns are Imbruvica all grades, Imbruvica Grade 3 or higher (Grade 3 or 4 in the hematologic table), ofatumumab all grades, and ofatumumab Grade 3 or higher (% of patients).
What side effects occurred with Imbruvica plus rituximab vs FCR (E1912)?
Applies to Adults with previously untreated (first-line) CLL/SLL
Note: Table columns on the E1912 page are Imbruvica plus rituximab (IR) all grades, IR Grade 3 or higher, FCR all grades, and FCR Grade 3 or higher (% of patients). FCR is fludarabine, cyclophosphamide, and rituximab. The laboratory values are from Table 14 of the Prescribing Information, whose PDF text lists the row names of each section and then each column of values in the same order (Imbruvica plus rituximab all grades, Grade 3 or 4, then FCR all grades, Grade 3 or 4). The hematology rows of the E1912 page are not quoted because the page labels its second row Peripheral edema, where Table 14 lists platelets decreased with the same values.
What side effects occurred with Imbruvica plus obinutuzumab (iLLUMINATE)?
Applies to Adults with previously untreated (first-line) CLL/SLL
Note: Table columns are Imbruvica plus obinutuzumab all grades, Imbruvica plus obinutuzumab Grade 3 or higher, chlorambucil plus obinutuzumab all grades, and chlorambucil plus obinutuzumab Grade 3 or higher (% of patients).
What side effects occurred with Imbruvica plus bendamustine-rituximab (HELIOS)?
Applies to Adults with previously treated (relapsed or refractory) CLL/SLL
Note: Table columns are Imbruvica plus BR all grades, Imbruvica plus BR Grade 3 or higher, placebo plus BR all grades, and placebo plus BR Grade 3 or higher (% of patients). BR is bendamustine and rituximab.